European Commission Approves Shire’s Gaucher Drug 09/15/2010Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: FDA, gaucher disease, Shire
MBBP client Shire Human Genetic Therapies was recently featured in a Boston Business Journal article. Shire’s Gaucher disease treatment VPRIV was approved by the European Commission, thereby allowing VPRIV to be marketed in thirty European countries. VPRIV approval by the U.S. Food and Drug Administration in March 2010 was fast-tracked due to the shortage of Genzyme Corporation’s Gaucher drug Cerezyme.
For more information, please visit Shire.